• Disease
  • Follicular
  • Follicular Lymphoma
  • Hervé Tilly

    Prominent publications by Hervé Tilly

    KOL Index score: 25774

    BACKGROUND: Patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL) have an unfavourable prognosis with few treatment options. Polatuzumab vedotin is an antibody-drug conjugate containing an anti-CD79B monoclonal antibody conjugated to the microtubule-disrupting agent monomethyl auristatin E. We aimed to assess the safety and clinical activity of polatuzumab vedotin in relapsed or refractory B-cell NHL and chronic lymphocytic leukaemia (CLL).

    METHODS: In this phase 1, ...

    Also Ranks for: Polatuzumab Vedotin Patients |  2 dose |  recommended phase |  hodgkin lymphoma |  combination rituximab
    KOL Index score: 17089

    BACKGROUND: Polatuzumab vedotin, an antibody-drug conjugate targeting the CD79b component of the B-cell receptor, has demonstrated activity as a single agent and in combination with rituximab in relapsed or refractory diffuse large B-cell lymphoma. In this study, we evaluated the safety and preliminary activity of polatuzumab vedotin in combination with rituximab or obinutuzumab and cyclophosphamide, doxorubicin, and prednisone (CHP) in patients with previously untreated diffuse large ...

    Also Ranks for: Polatuzumab Vedotin |  cell lymphoma |  diffuse large |  recommended phase |  grade 3
    KOL Index score: 16406

    BACKGROUND: Intensive chemotherapy for acute myelogenous leukemia (AML) continues to yield low rates of complete remission and survival among patients over the age of 65 years. Infection-related mortality is particularly high among these patients during the period of neutropenia that follows chemotherapy. We determined the effect of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) on mortality at eight weeks (the main end point) and the rate of complete ...

    Also Ranks for: Acute Myelogenous Leukemia |  placebo patients |  complete remission |  stimulating factor |  granulocyte colony
    KOL Index score: 16299

    BACKGROUND: Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has become the standard of care for elderly patients with diffuse large B-cell lymphoma. We aimed to ascertain if a dose-dense R-CHOP regimen administered every 2 weeks (R-CHOP14) was superior to the standard 3-week schedule (R-CHOP21).

    METHODS: We did a randomised phase 3 trial at 83 centres in four countries. 602 patients aged 60-80 years with untreated diffuse large ...

    Also Ranks for: Diffuse Large |  cell lymphoma |  3 trial |  standard rituximab |  rchop14 rchop21
    KOL Index score: 16064

    PURPOSE: To evaluate the prognostic value of cell of origin immunohistochemical markers and BCL2, BCL6, and c-MYC translocations in a homogeneous cohort of patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).

    PATIENTS AND METHODS: Patients with CD20+ DLBCL were enrolled in the randomized LNH98-5 and 01-5B Groupe d'Etude des Lymphomes de l'Adulte trials. Paraffin-embedded tumor samples of 119 ...

    Also Ranks for: Situ Hybridization |  diffuse large |  fluorescence lymphoma |  bcl2 bcl6 |  rchop patients
    KOL Index score: 15765

    PurposeThe role of interim PET/CT in guiding therapeutic strategies in diffuse large B-cell lymphoma (DLBCL) is debated, mainly because interpretation rules vary among centres. This study aimed to explore the reproducibility and confirm the prognostic value of early PET/CT using the Deauville criteria and ΔSUVmax.MethodsThis international confirmatory study retrospectively evaluated 114 patients with newly diagnosed DLBCL treated with a rituximab-containing regimen. All patients ...

    Also Ranks for: Deauville Criteria |  early pet |  cell lymphoma |  diffuse large |  interobserver agreement
    KOL Index score: 15519

    BACKGROUND: Romidepsin is a histone deacetylase inhibitor approved in the USA for patients with recurrent or refractory peripheral T-cell lymphoma and has shown activity in this setting with mainly haematological and gastrointestinal toxicity. Although it has limited efficacy, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy is widely used for treatment of de-novo peripheral T-cell lymphoma. We aimed to assess the safety, tolerability, and activity of romidepsin ...

    Also Ranks for: Cell Lymphoma |  untreated patients |  romidepsin chop |  2 study |  phase 1b
    KOL Index score: 15447

    BACKGROUND: Antibody-drug conjugates (ADCs) polatuzumab vedotin (pola) and pinatuzumab vedotin (pina) showed clinical activity and tolerability in phase 1 trials. The aim of this multicentre, open-label, phase 2 study was to compare rituximab plus pola (R-pola) or pina (R-pina) in patients with relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma.

    METHODS: In this phase 2 randomised study at 39 investigational sites in six countries, patients were randomly ...

    Also Ranks for: Pinatuzumab Vedotin |  follicular lymphoma |  complete response |  phase 2 |  pola patients
    KOL Index score: 15217

    BACKGROUND: Patients with follicular lymphoma can have long survival times, but disease progression typically occurs 3-5 years after initial treatment. We assessed the potential benefit of 2 years of rituximab maintenance after first-line treatment in patients with follicular lymphoma receiving a rituximab plus chemotherapy regimen.

    METHODS: The randomised, open-label PRIMA study was undertaken in 223 centres in 25 countries. 1217 patients with previously untreated follicular lymphoma ...

    Also Ranks for: 2 Years |  rituximab maintenance |  follicular lymphoma |  95 p0·0001 |  antibodies monoclonal
    KOL Index score: 15092

    BACKGROUND: The outcome of diffuse large B-cell lymphoma has been substantially improved by the addition of the anti-CD20 monoclonal antibody rituximab to chemotherapy regimens. We aimed to assess, in patients aged 18-59 years, the potential survival benefit provided by a dose-intensive immunochemotherapy regimen plus rituximab compared with standard treatment plus rituximab.

    METHODS: We did an open-label randomised trial comparing dose-intensive rituximab, doxorubicin, cyclophosphamide, ...

    Also Ranks for: 3 Trial |  diffuse large |  cell lymphoma |  standard chop |  doxorubicin cyclophosphamide
    KOL Index score: 14977

    PURPOSE: The prognostic value of [(18)F]fluorodeoxyglucose-positron emission tomography (PET), interpreted according to visual criteria, is a matter of debate for diffuse large B-cell lymphoma (DLBCL). Moreover, most published studies do not differentiate between patients treated with or without rituximab. We retrospectively investigated the prognostic value of PET performed in patients with DLBCL receiving chemotherapy plus rituximab. Images were interpreted both visually and by ...

    Also Ranks for: Cell Lymphoma |  positron emission |  patients dlbcl |  pet cycles |  fluorodeoxyglucose f18
    KOL Index score: 14914

    PURPOSE: We conducted an international, randomized, phase III trial to evaluate the efficacy and safety of consolidation with yttrium-90 ((90)Y)-ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma in first remission.

    PATIENTS AND METHODS: Patients with CD20(+) stage III or IV follicular lymphoma, who achieved a complete response (CR)/unconfirmed CR (CRu) or partial response (PR) after first-line induction treatment, were randomly assigned to receive (90)Y-ibritumomab ...

    Also Ranks for: Ibritumomab Tiuxetan |  consolidation therapy |  follicular lymphoma |  remission patients |  phase iii trial
    KOL Index score: 14826

    BACKGROUND: Lenalidomide plus rituximab is approved to treat patients with relapsed or refractory follicular lymphoma. Obinutuzumab has been shown to enhance antibody-dependent cellular cytotoxicity, phagocytosis, and direct B-cell killing better than rituximab. Our aim was to determine the activity and safety of lenalidomide plus obinutuzumab in previously treated patients with relapsed or refractory follicular lymphoma.

    METHODS: In this multicentre, single-arm, phase 2 study, patients ...

    Also Ranks for: Refractory Follicular |  cell lymphoma |  patients obinutuzumab |  response induction |  antibodies monoclonal


    Hervé Tilly: Influence Statistics

    Sample of concepts for which Hervé Tilly is among the top experts in the world.
    Concept World rank
    sic 26 #1
    trial lnh #1
    lymphoma acvbp #1
    suvmaxliver ipet4 #1
    application clinique #1
    detudes #1
    large bcell tomography #1
    lysa #1
    rchop21 elderly patients #1
    cycles acvbp #1
    vindesine young #1
    algorithm bcl2 expression #1
    chop pola #1
    cases t89q24p13 #1
    4 cycles chop #1
    tazemetostat study #1
    exportin 1 gene #1
    nhl 2 dose #1
    lymphoma types pmbl #1
    tmtv ecog #1
    expected subtype #1
    cultured child leukapheresis #1
    rdhap rdhaox #1
    5′mcr cases #1
    theoretical ree #1
    patients ezh2 status #1
    tmtv ρ #1
    harvested stem cells #1
    patients 2 trial #1
    ptcl outcome pit #1
    aa ipi #1
    dlbclmethodstmtv #1
    cdkn2a cdkn2b inactivation #1
    patients petnegative #1
    purposesalvage #1
    974 patients incidence #1
    1year maintenance obinutuzumab #1
    lnh037b #1
    large bcell illness #1
    insect humans lymphoma #1
    tts tvsr #1
    sic consolidation #1
    obinutuzumab galen #1
    t1418 rare entity #1
    ezh2wt cohort #1
    ngs pcnsl #1
    follicular lymphoma time #1
    tcell tmtv0 #1
    t1418 genes #1
    zbeam asct #1

    Key People For Follicular Lymphoma

    Top KOLs in the world
    Randy D Gascoyne
    cell lymphoma diffuse large gene expression
    T Andrew Lister
    follicular lymphoma bone marrow acute leukaemia
    Hervé Tilly
    consultancy honoraria board directors advisory committees
    Elaine S Jaffe
    cell lymphoma lymphoid neoplasms situ hybridization
    Richard I Fisher
    southwest oncology cell lymphoma consultancy funding
    Bertrand B Coiffier
    cell lymphoma monoclonal antibodies elderly patients

    Hervé Tilly:Expert Impact

    Concepts for whichHervé Tillyhas direct influence:Follicular lymphoma,  Cell lymphoma,  Diffuse large,  Large bcell,  Elderly patients,  Polatuzumab vedotin,  Rituximab maintenance.

    Hervé Tilly:KOL impact

    Concepts related to the work of other authors for whichfor which Hervé Tilly has influence:Cell lymphoma,  Diffuse large,  Monoclonal antibodies,  Elderly patients,  Bone marrow,  Acute myeloid leukemia.



    Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

    Centre Henri-Becquerel, Rouen, France | INSERM U1245, Centre Henri Becquerel, University of Rouen, Rouen, France. | Department of Hematology, Centre Henri Becquerel, Rouen, France. | Department of Hematology, Centre Henri Becquerel, University of Rou